BELANTAMAB MAFODOTIN

UNII:	DB1041CXDG
Formula:
Preferred Substance Name:	BELANTAMAB MAFODOTIN

2050232-20-5
BELANTAMAB MAFODOTIN [INN]
BELANTAMAB MAFODOTIN [JAN]
BELANTAMAB MAFODOTIN [MI]
BELANTAMAB MAFODOTIN [USAN]
BELANTAMAB MAFODOTIN [WHO-DD]
BELANTAMAB MAFODOTIN BLMF [WHO-DD]
BELANTAMAB MAFODOTIN-BLMF
BLENREP
GSK2857916
GSK-2857916
IMMUNOGLOBULIN G1, ANTI-(TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY PROTEIN TNFRSF17),(HUMANIZED MONOCLONAL GSK2857914 .GAMMA.1-CHAIN), DISULFIDE WITH HUMANIZED MONOCLONAL GSK2857914 .KAPPA.-CHAIN, DIMER, TETRATHIOETHER WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)-N-METHYL-L-VALYL-L-VALYL-(3R,4S,5S)-3-METHOXY-5-METHYL-4-(METHYLAMINO)HEPTANOYL-(.ALPHA.R,.BETA.R,2S)-.BETA.-METHOXY-.ALPHA.-METHYL-2-PYRROLIDINEPROPANOYL-L-PHENYLALANINE
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17 (B-CELL MATURATION PROTEIN, ANTIGEN CD269))HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN F.GAMMA.1 HEAVY CHAIN (1-451) (HUMANIZED VH (HOMO SAPIENS IGHV1-69*06 (84%) (IGHD)-IGHJ4*01 (86%)) (8.8.14) (1-121)-HOMO SAPIENS IGHG1*01 (122-451)) (224-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-214') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-33*01 (91%) IGKJ2*02 (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (230-230'':233-233'')-BISDISULFIDECONJUGATED, ON AN AVERAGE OF 4 CYSTEINYL RESIDUES (C), TO MONOMETHYL AURISTATIN F VIA MALEIMIDOCAPROYL LINKER.

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

BELANTAMAB MAFODOTIN

Synonyms and Mappings

Resources